
ECOGIES5508

A Phase III study of maintenance therapy with bevacizumab, pemetrexed or the combination after induction with carboplatin, paclitaxel and bevacizumab for advanced nonsquamous NSCLC

- Estimated primary completion: April 2018 (Target N = 1,282)
- Eligibility: Stage IIIB or IV NSCLC; predominant nonsquamous histology, with stable or better response after 4 courses of induction therapy; no cavitary lesions; prior adjuvant chemotherapy ≥12 months; prior radiation therapy ≥2 weeks



Principal Investigator: Suresh Ramalingam, MD ClinicalTrials.gov Identifier: NCT01107626

The 10th Annual

Winter Lung Cancer

Conference



DR PATEL

This is the most important trial after the negative PointBreak study, again evaluating 2 agents

for maintenance versus 1 and which is the superior maintenance therapy. So this is an important question. Hopefully we will obtain an answer earlier than initially projected, but this research question about 2 drugs versus 1 is important.



DR SOCINSKI

This is a timely trial with regard to maintenance therapy, and it's asking the right question.

Patients either receive continuation maintenance bevacizumab, switch maintenance with pemetrexed or a combination of switch and continuation maintenance with bevacizumab and pemetrexed after induction therapy. We don't have the trial open at Pittsburgh, but I would certainly endorse enrolling patients on it.

